

**To,**  
**BSE Limited,**  
Floor 25, P J Towers,  
Dalal Street, Mumbai – 400001  
**Script Code: 543963**

**Subject:** Outcome of the Board Meeting and Submission of the Audited Standalone Financial Results for the Half year and year ended March 31, 2025

**Ref:** Regulation 30, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with corresponding circulars and notifications issued thereunder.

Dear Sir/Madam,

This is to inform you that, the Board of Directors at their meeting held on today i.e. 29<sup>th</sup> May, 2025 started at 12:00 P.M. and Concluded at 12:30 P.M. at 5<sup>th</sup> Floor, Sakar 4, Opp. MJ Library, Ashram Road, Paldi, Ellisbridge, Ahmedabad-380006, Gujarat, India, interalia discussed and considered the following matters:

1. Approval of Standalone audited Financial Result for the Half year and Year ended on 31<sup>st</sup> March, 2025 as per Regulation 33 of the SEBI (LODR) Regulations, 2015 we are enclosing following.
  - a. Statement showing the Standalone Audited Financial Results for the Half Year and year ended March 31, 2025.
  - b. Auditors Report with unmodified opinion on Standalone Audited Financial Results for the year ended March 31, 2025
2. Appointment of CA Ismail Ibrahimbhai Lakhani (M/S. I I LAKHANI & CO), FRN NO: 143750W, Ahmedabad , as Internal Auditors of the Company to conduct the Internal Audit for the financial year 2025-26, A Brief Profile of M/S. I I LAKHANI & CO. is enclosed is enclosed herewith as 'Annexure B'.
3. Appointment of M/s. Murtuza Mandorwala & Associates, Practicing Company Secretary, as Secretarial Auditor of the Company for the period of Five year i.e from 2025-26 to 2029-30, A Brief Profile of M/s. Murtuza Mandorwala & Associates. is enclosed is enclosed herewith as 'Annexure C'

---

**Shelter Pharma Limited**

**Regd. Office & Works:** Shelternagar, Opp. Bus Station, Himatnagar-383001 Gujarat, India.

**Corporate Office:** 5<sup>th</sup> Floor, Sakar 4, Opp. MJ Library, Ashram Road, Paldi, Ellisbridge, Ahmedabad-380006, Gujarat, India.

**Email:** info@shelter.co.in **Phone:** +91 2772 240108/246995

**CIN:** L24233GJ2007PLC051956

A copy of the aforesaid financial results along with Auditors Report , and declaration of unmodified opinion as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019 is enclosed herewith as **Annexure A**.

Kindly take the above on record and oblige.

Thanking You.

**FOR, SHELTER PHARMA LIMITED**

**MUSTAQIM NISARAHMED SABUGAR**  
**MANAGING DIRECTOR**  
**DIN: 01456841**

**Date:** 29<sup>th</sup> May, 2025

**Place:** Ahmedabad

**CC:**

**Annexure A :** Financials , Declaration under Regulation 33(3)(d) of the SEBI {Listing Obligations and Disclosure Requirements} Regulations, 2015

**Annexure B :** Brief Profile of Internal Auditor

**Annexure C :** Brief Profile of Secretarial Auditor



**Mendajiwala & Co.**  
**Chartered Accountant**

**Annexure-A**

Ref. No. :

Date :

**Independent Auditor's Report on Audit of Standalone Financial Results of the  
SHELTER PHARMA LIMITED for the half year and year ended on 31<sup>st</sup> March, 2025 under Regulation  
33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as  
amended.**

To,  
The Board of Directors of  
Shelter Pharma Limited

**Opinion**


We have audited the accompanying standalone financial results of **SHELTER PHARMA LIMITED** (the "Company") (CIN : L24233GJ2007PLC051956) for the half year ended on 31<sup>st</sup> March 2025 ("The Financial Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanation given to us, the standalone financial results for the half year and year ended on 31<sup>st</sup> March, 2025

- It is presented in accordance with the requirements of regulation 33 of the listing regulations and
- Given a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India for the net profit and other financial information for the half year and year ended on 31<sup>st</sup> March, 2025.

**Basis for Opinion**

We conducted our audit in accordance with the Standard of Auditing ("SAs") specified under section 143(10) of the company's act, 2013 (the "Act"). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of Standalone Financial Results section of our report. We are independent of the company in accordance with the Codes of Ethics issued by the Institute of Chartered Accountant of India (the "ICAI") together with the ethical requirement that are relevant to our audit of the standalone financial results under the provisions of the Companies act, 2013 and the rules hereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and appropriate to provide a basis for our opinion.



## Management's Responsibility for the Financial Statements

This accompanying statement which includes the Standalone Financial Results for the half year and year ended 31<sup>st</sup> March, 2025 is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The standalone financial results for the half year and year ended 31<sup>st</sup> March, 2025 have been compiled from related audited standalone financial statements.

The company's Board of Directors are responsible for the matters stated in section of 134 (5) of the act with respect to the preparation of these standalone financial results that give a true and fair view of net profit and other financial information of the company in accordance with the accounting standards specified under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in india and in compliance with regulation 33 of the listing regulations. This responsibility is also includes maintenance of adequate accounting records in accordance with the provision of the Act for safeguarding the assets of the company and for preventing and detecting frauds and other irregularities selection and application of appropriate accounting policies, making judgment and estimates that are responsible and prudent and design implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud of error.

In preparing the financial statements, Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the company.

## Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the standalone financial results for the half year and year ended 31<sup>st</sup> March, 2025 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on effectiveness of company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosure made by the Board of Directors in terms of the requirements specified under Regulations 33 of the Listing Regulations.



- Conclude on the appropriateness of Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Annual Standalone Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure, and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.


#### Other Matters

The accompanying Statement includes the results for the half year ended 31<sup>st</sup> March, 2025, being the balancing figure between the audited figures in respect of the full financial year ended on 31<sup>st</sup> March, 2025, and the published unaudited year-to-date figures for the half year of the current financial year which were subject to limited review by us, as required under the Listing Regulations. Our opinion on the Audit of Standalone Financial Results for the year ended 31<sup>st</sup> March, 2025 is not modified in respect of this matter.

**For, Mendajiwal & Co.**

**Chartered Accountants**

**(Firm Reg. No.: 0135065W)**



**Mohammedsoel N Mendajiwal**

**Proprietor**

**Membership No.: 146324**

**UDIN: 25146324BM6XXK4485**



**Date: 29<sup>th</sup> May, 2025**

**Place: Ahmedabad**

**SHELTER PHARMA LIMITED**

CIN NO.: L24233GJ2007PLC051956

Opp : Bus Stand, Himmatnagar - 383001, Gujarat, India

**Audited Standalone Profit & Loss Statement for the half year and year ended 31st March, 2025**



(Amount in Lakh Except Share Data)

Sr. No	Particulars	Half year ended	Half year ended	Half year ended	Year Ended	
		31.03.2025	31.03.2024	30.09.2024	31.03.2025	31.03.2024
		(Audited)	(Un-Audited)	(Un-Audited)	(Audited)	(Audited)
	<b>Income</b>					
I	Revenue from operations	2,660.35	2,071.08	2,405.67	5,066.02	4,002.29
II	Other Income	0.34	0.25	0.21	0.55	0.39
III	<b>Total Income (I + II)</b>	<b>2,660.69</b>	<b>2,071.34</b>	<b>2,405.88</b>	<b>5,066.56</b>	<b>4,002.67</b>
IV	<b>Expenses</b>					
	(a) Cost of Material Consumed	1,938.37	1,459.56	1,776.98	3,715.35	2,885.38
	(b) Purchases of Stock-in-Trade					
	(c) Changes in inventories of finished goods work-in-progress and Stock-in-Trade	-14.92	17.58	2.57	-12.35	7.08
	(d) Employee Benefit Expense	99.43	48.14	62.33	161.76	86.61
	(e) Finance Cost	5.82		6.95	12.76	4.66
	(f) Depreciation & Amortised Expense	17.07	12.62	9.79	26.86	24.60
	(g) Other Expenses	120.33	117.17	74.15	194.48	166.08
	<b>Total Expenses</b>	<b>2,166.09</b>	<b>1,655.07</b>	<b>1,932.77</b>	<b>4,098.86</b>	<b>3,174.41</b>
V	Profit before exceptional and extraordinary items and tax (III - IV)	<b>494.59</b>	<b>416.27</b>	<b>473.11</b>	<b>967.70</b>	<b>828.26</b>
VI	Exceptional Items					
	Prior Period Items					
VII	Profit before extraordinary items and tax (V - VI)	<b>494.59</b>	<b>416.27</b>	<b>473.11</b>	<b>967.70</b>	<b>828.26</b>
VIII	CSR Provision					
IX	Profit before tax (VII - VIII)	<b>494.59</b>	<b>416.28</b>	<b>473.11</b>	<b>967.70</b>	<b>828.26</b>
X	<b>Tax expense:</b>					
	(1) Current tax	124.49	104.77	119.08	243.57	208.47
	(2) Deferred tax		-3.56	0.39	0.39	-3.56
	(3) Prior Period tax		3.33			3.33
	(4) Less : TDS					
XI	Profit/(Loss) for the period from continuing operations (IX - X)	<b>370.11</b>	<b>311.72</b>	<b>353.64</b>	<b>723.74</b>	<b>620.02</b>
XII	Profit/(loss) from discontinuing operations					
XIII	Tax expense of discounting operations					
XIV	Profit/(Loss) from Discontinuing operations (after tax) (XII - XIII)					
XIII	<b>Profit/(Loss) for the period (XI + XIV)</b>	<b>370.11</b>	<b>311.72</b>	<b>353.64</b>	<b>723.74</b>	<b>620.02</b>
XVI	<b>Earning per equity share of Rs.10 each</b>					
	(1) Basic	3.20	2.70	3.06	6.26	5.36
	(2) Diluted	3.20	2.70	3.06	6.26	5.36

FOR AND ON BEHALF OF THE BOARD,  
SHELTER PHARMA LIMITED



*Mustaqim N Sabugar*  
Mustaqim N Sabugar  
Chairman & Managing Director  
DIN: 01456841

*Shakil N Sabugar*  
Shakil N Sabugar  
Whole Time Director  
DIN: 01474868

Place: Ahmedabad  
Date: 29/05/2025

**SHELTER PHARMA LIMITED**

CIN NO. : L24233GJ2007PLC051956



Opp : Bus Stand, Himmatnagar - 383001, Gujarat, India

Statement of Standalone Assets &amp; Liabilities as on 31st March, 2025

(Amount In Lakh)

Particulars	As at 31.03.2025	As at 31.03.2024
	(Audited)	(Audited)
<b>I. EQUITY AND LIABILITIES</b>		
<b>(1) Shareholder's Funds</b>		
(a) Share Capital	1,155.98	1,155.98
(b) Reserves and Surplus	3,116.08	2,425.60
<b>(2) Non-Current Liabilities</b>		
(a) Long-Term Borrowings	93.16	57.32
(b) Deferred Tax Liabilities (Net)		
(c) Other Long Term liabilities		
(d) Long term Provisions	5.48	5.10
<b>(3) Current Liabilities</b>		
(a) Short-Term Borrowings	11.25	0.41
(b) 1. Trade Payables - others	125.07	70.12
2. Trade Payables - MSME		1.28
(c) Other Current Liabilities	6.80	6.16
(d) Short-Term Provisions	319.74	69.52
<b>Total Equity &amp; Liabilities</b>	<b>4,833.55</b>	<b>3,791.48</b>
<b>II. ASSETS</b>		
<b>(1) Non-Current Assets</b>		
<b>(a) Plant, Porperty &amp; Equipments and Intangible Assets</b>		
(i) Plant, Porperty & Equipments	595.14	357.07
(ii) Intangible Assets	1.00	0.88
(b) Non-current Investments	67.63	67.63
(c) Deferred tax assets (net)	3.17	3.56
(d) Long term loans and advances	838.75	390.46
(e) Other Non-Current Assets		
<b>(2) Current Assets</b>		
(a) Current investments		
(b) Inventories	1,289.52	992.90
(c) Trade receivables	947.46	885.01
(d) Cash and cash Equivalents	341.99	503.97
(e) Short-term loans and advances	571.71	389.40
(f) Other Current Assets	177.19	200.59
<b>Total Assets</b>	<b>4,833.55</b>	<b>3,791.48</b>

See accompanying notes to the financial statements

FOR AND ON BEHALF OF THE BOARD,  
SHELTER PHARMA LIMITED

Mustaqim N Sabugar  
Chairman & Managing Director  
DIN: 01456841

Shakil N Sabugar  
Whole Time Director  
DIN: 01474868

Place: Ahmedabad

Date: 29/05/2025

# SHELTER PHARMA LIMITED

CIN NO.: L24233GJ2007PLC051956



Opp : Bus Stand, Himmatnagar - 383001, Gujarat, India

## Standalone Cash Flow Statement for the year ended 31st March, 2025

(Amount In Lakh)

Particulars		As at 31.03.2025	As at 31.03.2024
		(Audited)	(Audited)
Net Profit / (Loss) Before Tax & Extra Ordinary Items:		967.70	828.26
<b>Adjustments For:</b>			
Depreciation & Amortization Expense		26.86	24.60
Provision for Gratuity			30.00
Bad debt			3.56
Deferred tax exp / income		(0.55)	(0.39)
Non-operating income (Intrest Received, etc)			
<b>Operating Profit Before Working Capital Changes</b>	<b>i.</b>	<b>994.01</b>	<b>886.04</b>
<b>Adjustments For:</b>			
(Increase)/ Decrease in Inventories		(296.62)	(206.56)
(Increase)/ Decrease in Trade Receivables		(62.45)	(65.54)
(Increase)/ Decrease in Short Term Loans & Advances		(182.30)	(389.30)
(Increase)/ Decrease in Other Current Assets		23.40	12.13
Increase/ (Decrease) in Trade Payable		53.66	24.66
Increase/ (Decrease) Other Current Liabilities		0.64	(256.21)
Increase/ (Decrease) Short Term Borrowings		10.84	(130.01)
Increase/ (Decrease) Short term provision		250.22	84.59
Increase/ (Decrease) Long term provision		0.38	
	<b>ii.</b>	<b>(202.22)</b>	<b>(926.25)</b>
<b>Cash Generated From Operations</b>	<b>i+ii</b>	<b>243.57</b>	<b>155.96</b>
Income Tax Paid			
<b>Net Cash From Operating Activities</b>	<b>(A)</b>	<b>548.22</b>	<b>(196.17)</b>
<b>B) CASH FLOW FROM INVESTING ACTIVITIES</b>			
Purchase of Fixed Assets		(265.05)	(85.19)
Purchase of Shares & Funds		-	-
Repayment of Long Term Loans & Advances		(448.29)	(369.34)
Intrest Received		0.55	0.13
<b>Net Cash From Investing Activities</b>	<b>(B)</b>	<b>(712.79)</b>	<b>(454.40)</b>
<b>C) CASH FLOW FINANCING ACTIVITIES</b>			
Proceeds from issuance of Share Capital		-	1,091.23
Increase / (Decrease) in Long term Borrowings		35.84	9.32
Dividend Paid		(38.15)	
Preliminary Expense (IPO Subsidy)		4.89	
<b>Net Cash From Financing Activities</b>	<b>(C)</b>	<b>2.59</b>	<b>1,100.55</b>
<b>Increase in Cash and Cash Equivalents</b>	<b>(D)</b>	<b>(161.99)</b>	<b>449.98</b>
<b>(A)+(B)+(C)</b>			
<b>Cash and Cash Equivalents at the Beginning of the Year</b>	<b>(E)</b>	<b>503.98</b>	<b>42.85</b>
<b>Cash and Cash Equivalents at the End of the Year</b>	<b>(D) +(E)</b>	<b>341.99</b>	<b>503.98</b>
<b>Components of Cash and Cash Equivalents:</b>			
Cash on Hand		77.51	84.75
Other Bank Balances		264.48	419.22
<b>Total</b>		<b>341.99</b>	<b>503.98</b>

### Notes:

- 1) The cash flow statement has been prepared Under indirect method as set out in the accounting standard 3 (AS-3), " Cash Flow Statement "
- 2) The previous year's figures have been regrouped wherever necessary.

FOR AND ON BEHALF OF THE BOARD,  
SHELTER PHARMA LIMITED



*(Signature)*

Mustaqim N Sabugar  
Chairman & Managing Director  
DIN: 01456841

*(Signature)*

Shakil N Sabugar  
Whole Time Director  
DIN: 01474868

Place: Ahmedabad  
Date: 29/05/2025

## **Explanatory notes to the Statement of audited Standalone Financial Results for the half year and year ended 31<sup>st</sup> March, 2025**

1. Audited Standalone Financial Results for the half year and year ended 31<sup>st</sup> March, 2025 have been prepared in accordance with the Accounting Standard prescribed under Section 133 of the Companies Act, 2013 read with Companies (Accounting Standards) Rules, as amended. These results have been Reviewed by the Audit Committee and approved by the Board of Directors at its meeting held 29<sup>th</sup> May, 2025. The Statutory Auditors of the company have issued audit report with unmodified opinion on the above results.
2. The figures for the half year ended March 31, 2025, as reported in these financial results are the balancing figures between audited figures in respect of full financial year and the figures for the period April 1, 2024 to September 30, 2024.
3. As per Accounting Standard 17 on "Segment Reporting" (AS 17), the company is engaged in Manufacturing of Pharmaceuticals.
4. As per MCA notification dated 16<sup>th</sup> February 2015 companies whose shares are listed on SME exchange as referred to Chapter IX of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2018 are exempted from compulsory requirement of adoption of IND-AS.
5. There are no investor complaints received for the period under review.
6. The Earning per shares (EPS) has been computed in accordance with the accounting standard on earning per share.
7. The figures for the corresponding Previous year/period figure have been regrouped/rearranged wherever necessary, to make them comparable.

**To,**  
**BSE Limited,**  
Floor 25, P J Towers,  
Dalal Street, Mumbai – 400001  
**Script Code: 543963**

**Subject:** Declaration in respect of Unmodified Opinion on Standalone Annual Audited Financial Results for the Financial Year Ended March 31, 2025

Dear Sir/Madam,

Pursuant to the Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, we hereby confirm and declare that M/s. Mendajiwala & Co, Chartered Accountants, Statutory auditors of the Company have issued an unmodified Audit Report on the Annual standalone Audited Financial Results of the Company, for the year ended March 31, 2025.

Kindly take the above on record and oblige.

Thanking You.

**FOR, SHELTER PHARMA LIMITED**

**MUSTAQIM NISARAHMED SABUGAR**  
**MANAGING DIRECTOR**  
**DIN: 01456841**

**Date:** 29<sup>th</sup> May, 2025

**Place:** Ahmedabad

**“Annexure-B”**

**Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**

<b>Sr. No.</b>	<b>Details of events that needs to be provided</b>	<b>Information of such event(s)</b>
1.	Reason for Change viz. Reappointment	Appointment: In Order to comply with the provision of section 138 of the Companies Act, 2013 and the requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2.	Date of Reappointment	29 <sup>th</sup> May, 2025
3.	Brief Profile	CA Ismail Ibrahimbhai Lakhani (M/S. I I LAKHANI & CO), FRN NO: 143750W , Chartered Accountants Firm Working For more than 08 Years in the field of Company Audit, Tax Audit, Accounting, GST Audit, Company Law Matters, Income Tax Matters, Sales Tax Matters, Sales Tax Matters, Transactional Audit etc. and valuation work from last 3 years.
4.	Term of Reappointment	For F.Y. 2025-26

**Shelter Pharma Limited**

**Regd. Office & Works:** Shelternagar, Opp. Bus Station, Himatnagar-383001 Gujarat, India.

**Corporate Office:** 5<sup>th</sup> Floor, Sakar 4, Opp. MJ Library, Ashram Road, Paldi, Ellisbridge, Ahmedabad-380006, Gujarat, India.

**Email:** info@shelter.co.in **Phone:** +91 2772 240108/246995

**CIN:** L24233GJ2007PLC051956

### “Annexure-C”

**Disclosure of information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.**

Sr. No.	Details of events that needs to be provided	Information of such event(s)
1.	Reason for Change viz. Reappointment	Reappointment: In Order to comply with the provision of section 204 of the Companies Act, 2013 and the requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2.	Date of Reappointment	Date: 29 <sup>th</sup> May, 2025
3.	Brief Profile	Attached as Annexure II
4.	Term of Reappointment	For the period of Five year i.e from 2025-26 to 2029-30

### Annexure II

NAME	M/S Murtuza Mandorwala & Associates
Date Reappointment	29 <sup>th</sup> May, 2025
Term of Reappointment	For the period of Five year i.e from 2025-26 to 2029-30
Address	B-503, Sivanta One, Pritamnagar Cross road, Near V.S. Hospital, Ellisbridge, Ahmedabad-380006
Contact	09409020523
Qualification	<ul style="list-style-type: none"> <li>✓ Member of Institute of Company Secretaries of India</li> <li>✓ Bachelor in Commerce from Gujarat University</li> <li>✓ Masters in Commerce from Indira Gandhi National University</li> <li>✓ Bachelor of Law from Gujarat University</li> <li>✓ DLP: Diploma in Labour Practice from Gujarat</li> </ul>

### Shelter Pharma Limited

**Regd. Office & Works:** Shelternagar, Opp. Bus Station, Himatnagar-383001 Gujarat, India.

**Corporate Office:** 5<sup>th</sup> Floor, Sakar 4, Opp. MJ Library, Ashram Road, Paldi, Ellisbridge, Ahmedabad-380006, Gujarat, India.

**Email:** info@shelter.co.in **Phone:** +91 2772 240108/246995

**CIN:** L24233GJ2007PLC051956

Area of Practice	Corporate & LLP Laws, SME Advisory, Compliance, Due Diligence, FDI & FEMA advisory, NBFC Laws, Capital Markets & Securities Laws Advisory, Taxation, Audit & Certifications, Legal Compliances, Corporate Governance, Corporate Social Responsibility and allied services.
Service Provided	Corporate & LLP Laws, SME Advisory, Compliance, Due Diligence, FDI & FEMA advisory, NBFC Laws, Capital Markets & Securities Laws Advisory, Taxation, Audit & Certifications, Legal Compliances, Corporate Governance, Corporate Social Responsibility and allied services.
Peer-review no.	1615/2021
M. No.	F10745
C.P.No.	14284

**Shelter Pharma Limited**
**Regd. Office & Works:** Shelternagar, Opp. Bus Station, Himatnagar-383001 Gujarat, India.

**Corporate Office:** 5<sup>th</sup> Floor, Sakar 4, Opp. MJ Library, Ashram Road, Paldi, Ellisbridge, Ahmedabad-380006, Gujarat, India.

**Email:** info@shelter.co.in **Phone:** +91 2772 240108/246995

**CIN:** L24233GJ2007PLC051956